1. Home
  2. M vs ABVX Comparison

M vs ABVX Comparison

Compare M & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Macy's Inc

M

Macy's Inc

HOLD

Current Price

$25.28

Market Cap

6.7B

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$99.35

Market Cap

7.2B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
M
ABVX
Founded
1830
2013
Country
United States
France
Employees
N/A
69
Industry
Department/Specialty Retail Stores
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
6.7B
7.2B
IPO Year
2002
N/A

Fundamental Metrics

Financial Performance
Metric
M
ABVX
Price
$25.28
$99.35
Analyst Decision
Hold
Buy
Analyst Count
13
13
Target Price
$20.09
$131.31
AVG Volume (30 Days)
7.2M
2.3M
Earning Date
05-27-2026
03-23-2026
Dividend Yield
3.97%
N/A
EPS Growth
12.08
N/A
EPS
0.23
N/A
Revenue
$22,621,000,000.00
N/A
Revenue This Year
N/A
$52.14
Revenue Next Year
N/A
$4,132.27
P/E Ratio
$108.63
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.99
$5.88
52 Week High
$25.65
$148.83

Technical Indicators

Market Signals
Indicator
M
ABVX
Relative Strength Index (RSI) 71.92 43.56
Support Level $16.74 $87.60
Resistance Level N/A $131.50
Average True Range (ATR) 1.09 7.76
MACD 0.32 -1.02
Stochastic Oscillator 93.12 45.14

Price Performance

Historical Comparison
M
ABVX

About M Macy's Inc

Founded in 1858 and based in New York City, Macy's operates about 430 eponymous stores, 60 stores under the Bloomingdale's (full-price and outlet) and Bloomie's names, and more than 170 freestanding Bluemercury specialty beauty stores. Macy's also operates e-commerce sites and licenses Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances constituted 64% of 2025 net retail sales.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.

Share on Social Networks: